In:
Cancer, Wiley, Vol. 119, No. 14 ( 2013-07-15), p. 2555-2563
Abstract:
This randomized, phase 2 trial shows that objective response rates and progression‐free and overall survival are numerically inferior in patients who receive axitinib plus combined 5‐fluorouracil, leucovorin, and oxaliplatin (FOLFOX‐6) versus bevacizumab plus FOLFOX‐6. Shorter treatment duration and more discontinuations because of adverse events observed in the axitinib arm suggest that vascular endothelial growth factor receptor tyrosine kinase inhibitors plus chemotherapy may be somewhat less well tolerated than bevacizumab plus chemotherapy.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v119.14
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Bookmarklink